Compare e l f Beauty Inc (ELF) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
e l f Beauty Inc vs IDEXX Laboratories, Inc. — how do they compare? e l f Beauty Inc trades at $107.57 (market cap $6.25B), while IDEXX Laboratories, Inc. trades at $512.76 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.5× e l f Beauty Inc's market cap, and e l f Beauty Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold e l f Beauty Inc for 25 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| ELF | IDXX | |
|---|---|---|
Market Cap | $6.25B | $40.43B |
Volume | 1,099,552 | 692,164 |
Sector | Consumer Staples | Health |
52-Week High | $144.97 | $766.68 |
52-Week Low | $49.57 | $504.70 |
Typical Hold Time | 25 Days | 46 Days |
Enterprise Value | $6.84B | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELF trades at $105.03, up 2.18% today, with a bullish technical signal from moving averages and strong recent earnings beats. The company shows robust revenue growth, expanding internationally with the rhode brand launch in Europe via Sephora, though net margins are thin at 3.38%. Valuation ratios are elevated with a P/E of 108.12, reflecting high growth expectations. Analyst consensus is mixed with a 48.27% buy rating but a price target of $95.91 below the current price.
Outlook: ELF's aggressive marketing and global expansion present growth opportunities, but the stock's premium valuation and high P/E pose risks if growth slows. Investor sentiment is cautiously optimistic, supported by institutional buying, yet overbought RSI levels suggest near-term volatility. Key risks include execution of international strategy and competitive pressures in the beauty sector.
IDEXX Laboratories (IDXX) trades at $506.67, down 1.7% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding expectations of $3.94. Recent developments include the acquisition of CoVetAI to enhance veterinary workflow intelligence and expansion of diagnostic testing platforms internationally. Revenue growth remains robust at $4.3 billion for 2025, with net income margins exceeding 25%.
The stock presents a compelling growth story with strong profitability metrics and analyst consensus pointing to significant upside potential (average price target $665). However, current technical weakness and premium valuations (P/E 36.06) create near-term headwinds. Key risks include foreign exchange pressures and potential slowdown in U.S. veterinary visits, while institutional ownership trends show mixed positioning among major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
